Biogen begins executive search to replace CEO
ValleraTo/iStock via Getty Images


With its 1Q 2022 results, Biogen (NASDAQ:BIIB) announced on Tuesday that the company has started a search for a new Chief Executive Officer.
However, the current CEO, Michel Vounatsos, will continue to lead the company and serve its board until a successor is appointed.

âWe are pleased that Michel will continue to lead the Company until a successor is appointed and help to ensure a seamless transition to a new chief executive, Chairman of the board Stelios Papadopoulos noted.
âThis is the right time to transition to a new leader who will build Biogenâs next chapter on the strong foundation existing today,â he added.
Mr. Vounatsos was appointed as Biogen (BIIB) CEO in 2017 and presided over the company as the FDA approved its Alzheimerâs medication Aduhelm under controversial circumstances.
Biogen (BIIB) shares are trading lower in the pre-market after the companyâs 1Q 2022 earnings that fell short of expectations.

For the quarter, the company reported ~$2.8M revenue from Aduhelm compared to ~$1.0M in the preceding quarter.